| Literature DB >> 29386698 |
Yingli Fu1, Yaqin Yu1, Yanhua Wu2, Yueyue You1, Yangyu Zhang1, Changgui Kou1.
Abstract
Metabolic syndrome (MetS) is a significant health care problem worldwide and is characterized by increased fasting glucose and obesity. Resistin is a protein hormone produced both by adipocytes and immunocompetent cells, including those residing in adipose tissue, and is believed to modulate glucose tolerance and insulin action. This study examined the association of resistin gene polymorphisms, rs1862513 and rs3745368, and related haplotypes with the development of metabolic syndrome in a Han Chinese population. This case-control study was performed on 3792 subjects, including 1771 MetS cases and 2021 healthy controls from the Jilin province of China. Metabolic syndrome was defined according to the criteria of the International Diabetes Federation (IDF). Logistic regression analysis was used to estimate the relationship between gene polymorphism and MetS. Our results showed that there were no significant associations between MetS and the genotype distributions in four kinds of inheritance models, allele frequencies, and related haplotypes of resistin gene polymorphisms rs1862513 and rs3745368 (all p values > 0.05). Based on our study findings, we concluded that mutations in resistin genes are not associated with the presence of MetS in a Han Chinese population from Jilin province in China.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29386698 PMCID: PMC5745751 DOI: 10.1155/2017/1638769
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.434
Demographic and biochemical parameters of study population.
| Parameters | Case ( | Control ( |
|
|
|---|---|---|---|---|
| Age (year) | 49.49 ± 0.23 | 49.45 ± 0.21 | 0.115 | 0.907 |
| Gender | ||||
| Male | 884 (49.9) | 1015 (50.2) | 0.036 | 0.850 |
| Female | 887 (50.1) | 1006 (49.8) | ||
| BMI (kg/m2) | 27.21 ± 0.07 | 21.90 ± 0.06 | 54.533 | <0.001∗ |
| WC (cm) | 91.28 ± 0.19 | 75.02 ± 0.16 | 65.743 | <0.001∗ |
| HC (cm) | 99.73 ± 0.15 | 90.74 ± 0.13 | 45.067 | <0.001∗ |
| HR (beat/min) | 79.06 ± 0.26 | 74.26 ± 0.25 | 13.230 | <0.001∗ |
| SBP (mm Hg) | 144.78 ± 0.45 | 120.22 ± 0.35 | 42.720 | <0.001∗ |
| DBP (mm Hg) | 87.93 ± 0.26 | 74.61 ± 0.21 | 39.805 | <0.001∗ |
| TG (mg/dL) | 3.23 ± 0.06 | 1.09 ± 0.01 | 34.188 | <0.001∗ |
| TC (mg/dL) | 5.26 ± 0.03 | 4.72 ± 0.02 | 15.272 | <0.001∗ |
| LDL-C (mg/dL) | 3.08 ± 0.02 | 2.84 ± 0.02 | 8.488 | <0.001∗ |
| HDL-C (mg/dL) | 1.16 ± 0.01 | 1.62 ± 0.01 | −43.347 | <0.001∗ |
| Fasting glucose (mg/dL) | 6.64 ± 2.44 | 4.85 ± 0.98 | 28.918 | <0.001∗ |
Data are given as mean ± SD or frequency (% subjects); p values were analyzed using Student's t-test or nonparametric test. ∗A value of p < 0.05 was considered statistically significant. BMI: body mass index; WC: waist circumference; HC: hip circumference; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; TG: triglyceride; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol.
Distributions of genotypes/alleles and the risk estimates for the variant genotypes/alleles.
| SNP | Genotype | Cases (%) | Controls (%) | Crude OR (95% CI) |
| Adjusted OR∗ (95% CI) |
|
|---|---|---|---|---|---|---|---|
| rs1862513 | CC | 191 (10.78) | 218 (10.79) | 1 | 0.906 | 1 | 0.505 |
| GG | 800 (45.17) | 918 (45.42) | 0.99 (0.80–1.23) | 0.98 (0.76–1.25) | |||
| CG | 780 (44.04) | 885 (43.79) | 1.01 (0.81–1.25) | 1.00 (0.78–1.27) | |||
| C-allele | 1162 (32.81) | 1321 (32.68) | 1 | 0.908 | 1 | 0.727 | |
| G-allele | 2380 (76.19) | 2721 (67.32) | 0.99 (0.90–1.10) | 0.982 (0.89–1.09) | |||
|
| |||||||
| rs37445368 | GG | 1304 (73.63) | 1471 (72.79) | 1 | 0.541 | 1 | 0.536 |
| AA | 33 (1.86) | 37 (1.83) | 1.01 (0.63–1.62) | 0.98 (0.58–1.66) | |||
| GA | 434 (24.51) | 513 (25.38) | 0.95 (0.82–1.11) | 0.95 (0.81–1.12) | |||
| G-allele | 3042 (85.88) | 3455 (85.48) | 1 | 0.615 | 1 | 0.588 | |
| A-allele | 500 (14.12) | 587 (14.52) | 0.97 (0.85–1.10) | 0.96 (0.84–1.11) | |||
OR: odds ratio; CI: confidence interval. ∗Adjusted for age, sex, smoking status, and alcohol consumption.
Genotype distribution by different inheritance models and odds ratio estimate.
| SNP | Genotype | Inheritance model | Case | Control | Adjusted OR (95% CI)∗ |
|
|---|---|---|---|---|---|---|
| rs1862513 | C/C | Codominant | 191 (10.8%) | 218 (10.8%) | 1 | 0.96 |
| G/G | 800 (45.2%) | 918 (45.4%) | 0.98 (0.79–1.21) | |||
| G/C | 780 (44%) | 885 (43.8%) | 0.99 (0.80–1.23) | |||
| C/C | Dominant | 191 (10.8%) | 218 (10.8%) | 1 | 0.88 | |
| G/G-C/G | 1580 (89.2%) | 1803 (89.2%) | 0.98 (0.80–1.21) | |||
| C/C-G/G | Recessive | 991 (56%) | 1136 (56.2%) | 1 | 0.86 | |
| G/C | 780 (44%) | 885 (43.8%) | 1.01 (0.89–1.15) | |||
| C/C-G/C | Overdominant | 971 (54.8%) | 1103 (54.6%) | 1 | 0.78 | |
| G/G | 800 (45.2%) | 918 (45.4%) | 0.98 (0.86–1.12) | |||
|
| ||||||
| rs3745368 | G/G | Codominant | 1304 (73.6%) | 1471 (72.8%) | 1 | 0.84 |
| A/A | 33 (1.9%) | 37 (1.8%) | 0.97 (0.60–1.57) | |||
| A/G | 434 (24.5%) | 513 (25.4%) | 0.96 (0.82–1.11) | |||
| G/G | Dominant | 1304 (73.6%) | 1471 (72.8%) | 1 | 0.56 | |
| A/A-A/G | 467 (26.4%) | 550 (27.2%) | 0.96 (0.83–1.11) | |||
| G/G-A/A | Recessive | 1337 (75.5%) | 1508 (74.6%) | 1 | 0.56 | |
| A/G | 434 (24.5%) | 513 (25.4%) | 0.96 (0.83–1.11) | |||
| G/G-A/G | Overdominant | 1738 (98.1%) | 1984 (98.2%) | 1 | 0.95 | |
| A/A | 33 (1.9%) | 37 (1.8%) | 0.98 (0.61–1.59) | |||
OR: odds ratio; CI: confidence interval. ∗Adjusted for age, sex, smoking status, and alcohol status.
Associations between RETN haplotypes and risk of MetS.
| rs1862513 | rs3745368 | Frequency | Adjusted OR (95%) |
| ||
|---|---|---|---|---|---|---|
| Total | Case | Control | ||||
| G | G | 0.6400 | 0.6395 | 0.6404 | 1 | |
| C | G | 0.2167 | 0.2193 | 0.2144 | 1.03 (0.92–1.16) | 0.60 |
| C | A | 0.1107 | 0.1088 | 0.1124 | 0.97 (0.84–1.13) | 0.73 |
| G | A | 0.0326 | 0.0324 | 0.0328 | 0.96 (0.72–1.30) | 0.81 |